


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY DKT. : CM2-104033-006 )  
APPLICANT : Kirk M. Maxey, et al. )  
SERIAL NO. : 09/776,574 )  
FILED : February 1, 2001 )  
FOR : Internal 1,15 Lactones of Fluprostenol )  
and Related Prostaglandin F<sub>2α</sub> Analogs )  
and Their Use in the Treatment of )  
Glaucoma and Intraocular Hypertension )

Commissioner For Patents  
Washington, D. C. 20231




#626  
RECEIVED  
SEP 28 2001  
TECH CENTER 1600/2900

\*\*\* \*\*

CERTIFICATE OF MAILING

*The undersigned hereby certifies that this document has been forwarded via First Class Mail, postage prepaid mail to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on September 24, 2001.*

  
Benita J. Rohm, REG. NO. 28,664

\*\*\* \*\*

INFORMATION DISCLOSURE STATEMENT

SIR:

In compliance with the duty of disclosure according to 37 C.F.R. §1.56, §1.97, and §1.98, Applicant presents herein prior art references which are believed at this time to be relevant to the subject matter of the instant patent application. A copy of the references, which are listed in the annexed PTO-1449 (equivalent) form, is enclosed.

The enclosed references were cited in an International Search Report mailed on May 30, 2001 and performed by the European Patent Office (copy enclosed).

Ref. BF, which was cited in the Chemical Abstracts Service (Ref. BH) is in the Japanese language. Ref. BA and Ref. BC, which are United States patents, are provided herein as "family members" in the English language that are related to Ref. BF.

**INFORMATION DISCLOSURE STATEMENT**  
**USSN 09/776,574; CM2-104033-006**

This Information Disclosure Statement is being filed prior to the issuance of a first Office Action for the application. Accordingly, no fee is necessary.

Should a fee be necessary, the Commissioner is authorized to charge Deposit Account 50-0720 as required.


In view of the foregoing, it is respectfully requested that the Examiner examine the present application, allow the claims, and pass the application for issue. If the Examiner believes that the prosecution of this case can be expedited by a telephone interview, the Examiner is requested to call the undersigned attorney at the telephone number indicated hereinbelow.

Respectfully submitted,



Dated: September 24, 2001

Benita J. Rohm  
**Rohm & Monsanto, P.L.C.**  
660 Woodward Avenue  
Suite 1525  
Detroit, MI 48226  
Telephone (313) 965-1976  
Telecopier (313) 965-1951

**LIST OF PRIOR ART CITED BY APPLICANT**

PTO-1449 (EQUVALENT)

Atty Docket:

SN:

Applicant:

Filing date:

Sheet 1 of 1

CM2

09/776,574

Maxey, *et al.*

02/01/01

TECH CENTER 1600/2900

SEP 28 2001

RECEIVED

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	REF.	DOCUMENT NO.	DATE	NAME	CLASS / SUB CLASS	FILING DATE IF APPROPRIATE
	BA	4,116,979	09/26/78	Razdan, <i>et al.</i>	260/345.3	02/07/77
	BB	4,049,678	09/20/77	Peterson	260/343.41	03/29/76
	BC	4,025,516	05/24/77	Razdan, <i>et al.</i>	260/345.3	11/28/75

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	REF.	DOCUMENT NO.	DATE	COUNTRY	CLASS / SUB CLASS	TRANSLATION YES / NO
	BD	0 639 563 A2	02/22/95	EP	C07C 405/00	N/A
	BE	1 554 026	10/17/79	GB	C07D 315/00	N/A
	BF	52-001034 A	01/06/77	JP	A61K 31/335	no

**OTHER PRIOR ART** *(Including Author, Title, Date, Pertinent Pages, etc.)*

EXAMINER INITIAL	REF.	
	BG	Bundy, <i>et al.</i> , Synthesis and Biological Activity of Prostaglandin Lactones, <i>J. Med. Chem.</i> , 26:8, pp. 1089-99 (1983)
	BH	Prostaglandin Lactones, <i>Chemical Abstracts Service</i> , Upjohn Co., USA, database accession no. 88:104768 XP002166932 re JP 52-001034 A (January 6, 1977)

EXAMINER

DATE CONSIDERED